000 | 01976 a2200601 4500 | ||
---|---|---|---|
005 | 20250515014915.0 | ||
264 | 0 | _c20060314 | |
008 | 200603s 0 0 eng d | ||
022 | _a0017-5749 | ||
024 | 7 |
_a10.1136/gut.2005.081950b _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aTravis, S P L | |
245 | 0 | 0 |
_aEuropean evidence based consensus on the diagnosis and management of Crohn's disease: current management. _h[electronic resource] |
260 |
_bGut _cMar 2006 |
||
300 |
_ai16-35 p. _bdigital |
||
500 | _aPublication Type: Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAdrenal Cortex Hormones _xtherapeutic use |
650 | 0 | 4 |
_aAminosalicylic Acids _xtherapeutic use |
650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
650 | 0 | 4 | _aClinical Trials as Topic |
650 | 0 | 4 |
_aCrohn Disease _xdrug therapy |
650 | 0 | 4 | _aDrug Resistance |
650 | 0 | 4 | _aEvidence-Based Medicine |
650 | 0 | 4 |
_aGastrointestinal Agents _xtherapeutic use |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
650 | 0 | 4 | _aInfliximab |
650 | 0 | 4 |
_aMethotrexate _xtherapeutic use |
650 | 0 | 4 | _aPatient Selection |
650 | 0 | 4 |
_aPurines _xtherapeutic use |
650 | 0 | 4 | _aRemission Induction |
650 | 0 | 4 | _aSecondary Prevention |
700 | 1 | _aStange, E F | |
700 | 1 | _aLémann, M | |
700 | 1 | _aOresland, T | |
700 | 1 | _aChowers, Y | |
700 | 1 | _aForbes, A | |
700 | 1 | _aD'Haens, G | |
700 | 1 | _aKitis, G | |
700 | 1 | _aCortot, A | |
700 | 1 | _aPrantera, C | |
700 | 1 | _aMarteau, P | |
700 | 1 | _aColombel, J-F | |
700 | 1 | _aGionchetti, P | |
700 | 1 | _aBouhnik, Y | |
700 | 1 | _aTiret, E | |
700 | 1 | _aKroesen, J | |
700 | 1 | _aStarlinger, M | |
700 | 1 | _aMortensen, N J | |
773 | 0 |
_tGut _gvol. 55 Suppl 1 _gp. i16-35 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1136/gut.2005.081950b _zAvailable from publisher's website |
999 |
_c16093419 _d16093419 |